Moderna returns to profit as Q3 revenue rises 29%
Moderna reported Q3 2026 revenue of $1.313B, up 29% YoY, and net income of $162M, reversing a $200M loss from the prior year. Earnings per share were $0.38, up from a loss of $0.51. The company raised its full-year growth forecast and has $8B in cash. Moderna's Phase 3 study with Merck's KEYTRUDA showed a 42% reduction in melanoma recurrence risk, but its norovirus vaccine program did not meet early goals.
How this was made
The 30-second read
Why it matters
The earnings surprise could trigger short-covering and new buying, especially given the company's cash position of $8B.
Market read
Earnings-driven catalyst for Moderna and potential spillover to biotech sector.
What to watch
Potential headwinds from competition in mRNA therapeutics and regulatory timelines could temper upside.
Background
Moderna's Q3 earnings mark a turnaround after a loss in the prior year, with expanded vaccine approvals in North America.
Ticker impact
Moderna reported Q3 2026 revenue of $1.313B, a 29% YoY increase, and a net profit of $162M, marking a return to profitability.
likely upward pressure as the market prices in the profit rebound and revenue growth
The surprise profit and strong revenue growth exceed prior expectations, providing a clear catalyst for buying interest.
Market effects
Positive earnings may lift the broader biotech and mRNA vaccine sector.
U.S. biotech stocks could see modest gains following the release.
Moderna's results may influence global vaccine developers and related equity markets.
Counterpoint
Investors may be cautious if guidance remains modest despite the profit swing.
Key entities
- companyModerna
Biotech firm developing mRNA vaccines and therapeutics.
